Holen Sie sich die Stockscreener-App
44.23
2.12%
0.92
Handel nachbörslich:
44.32
0.09
+0.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb: Declines Have Gone Too Far (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu - Insider Monkey
Bristol-Myers Squibb: No Respect For Blowout EarningsBuy The Richer Dividend Yields - Seeking Alpha
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges - TipRanks
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz - pehub.com
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Emerging Trends Highlight Shift Towards Immunotherapy in Testicular Cancer - GlobeNewswire Inc.
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: Robust Growth and Strategic ... By GuruFocus - Investing.com Canada
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: - GuruFocus
What are the technical indicators suggesting about Bristol Myers Squibb Company Equity RightAI Powered Review For 2025 - jammulinksnews.com
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 - Insider Monkey
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol Myers tops revenue expectations on strength of older drugs, shares fall By Reuters - Investing.com
Earnings call transcript: Bristol-Myers Squibb Q2 2025 sees earnings beat but stock dips - Investing.com Canada
Bristol Myers tops revenue expectations on strength of older drugs, shares fall - MarketScreener
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - Yahoo Finance
Bristol Myers posts better-than-expected second quarter results on strength of top sellers - Bilyonaryo Business News
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic - Yahoo Finance
Bristol Myers raises guidance as Q2 results beat forecasts - The Pharma Letter
Bristol Myers Squibb Q2 2025 Earnings Call Transcript - MarketBeat
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion - Yahoo Finance
Is Wall Street Bullish or Bearish on Bristol-Myers Stock? - Yahoo Finance
Bristol-Myers Squibb stock hits 52-week low at 43.89 USD - Investing.com Nigeria
Bristol-Myers Squibb Co reports results for the quarter ended June 30Earnings Summary - TradingView
Bristol Myers Squibb's 2025 EPS Target Revisions: A Strategic Realignment for Long-Term Growth - AInvest
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations - The Wall Street Journal
Bristol-Myers Squibb Co Surpasses Revenue Estimates with $12.3 Billion, Non-GAAP EPS of $1.46 Exceeds Expectations - GuruFocus
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio - Investing.com Nigeria
Bristol-Myers Squibb Q2 2025 slides: Growth portfolio drives revenue, guidance raised - Investing.com Australia
Bristol-Myers Squibb earnings beat by $0.40, revenue topped estimates - Investing.com Nigeria
Latest Q2 2025 Financial Results: Bristol Myers Squibb Releases Earnings Report and Investor Call Details - Stock Titan
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA - Yahoo Finance
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone - Benzinga
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday - Benzinga
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration - MSN
Bristol Myers Squibb: A Stock with Potential Amid Challenges - AOL.com
Bristol-Myers Squibb (BMY) Gets a Hold from Cantor Fitzgerald - The Globe and Mail
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect - Yahoo Finance
Bain leads $300M bet on biotech developing BMS drugs - Axios
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - PharmExec
Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income - Insider Monkey
Bain Capital, Bristol Myers Squibb launch biotech with $300M - The Business Journals
October 17th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating - Investing.com Nigeria
Bristol Myers, Bain Capital form new company to develop immunology drugs - Reuters
Technical Bounce Expected in Bristol Myers Squibb Company Equity Right Next WeekTrade Scanner With Buy Zone Alerts Flagged - metal.it
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating By Investing.com - Investing.com South Africa
BMS and Bain Capital create new company - The Pharma Letter
BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bain leads $300M investment in startup built on Bristol Myers immune drugs - BioPharma Dive
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients - BioSpace
4 Dead After Gunman Attacks NYC Office Building: Live Updates - New York Magazine
Bristol Myers Squibb and Bain Capital Create New Company - citybiz
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):